FLT1 binding proteins and methods of use
TW202639588APending Publication Date: 2026-10-01AMGEN INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114137227
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-28
- Filing Date
- 2025-09-26
- Publication Date
- 2026-10-01
Smart Images

Figure TWG2TA001078319_001 
Figure TWG2TA001078319_002 
Figure TWG2TA001078319_003
Abstract
Provided herein are FLT1 binding proteins, as well as related nucleic acids, vectors, host cells, pharmaceutical compositions and kits. The present disclosure additionally provides methods of treating a subject in need thereof, including subjects in need of treatment for PAD, CLI, ANOCA, or heart failure (HF). Further provided are methods of increasing VEGF-mediated and / or PlGF-mediated signal transduction in a subject, which, in turn, increases blood flow, capillary density, capillary or coronary growth, and / or cardiac perfusion in the subject. The present disclosure further provides methods of reducing blood pressure and risk of heart failure in a subject. In exemplary embodiments, each of the methods comprise administering to the subject a pharmaceutical composition of the present disclosure. In various embodiments, the pharmaceutical composition comprises a FLT1 binding protein of the present disclosure.
Need to check novelty before this filing date? Find Prior Art
